Skip to main content

Table 3 Summary of studies showing mean and median total IgE levels in subjects with CSU undergoing treatment with omalizumab or placebo

From: Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review

Reference (author, year)

Region

Definition of CSU in weeks

Treatment

Number of CSU subjects undergoing IgE testing

Mean total IgE (kU/L) (SD)

Median Total IgE (kU/L) (IQR)

% of subjects previously on systemic corticosteroids (SC)

Number of antihistamine (AH) or systemic corticosteroid-free days

Range (kU/L)

Maurer, 2011 [68]

Germany

> 6

Omalizumab

27

211 (158)

   

Placebo

22

181 (136)

Saini, 2011 [69]

USA and Germany

> 6

Omalizumab or Placebo

90

215 (432)

88.5

2–3510

Nam, 2012 [70]

Korea

> 6

Omalizumab

26

248 (275)

42.3

Kaplan, 2013 [71]

Various countries

> 6

Omalizumab or Placebo

335

159 (288)

78

57.9

16

1–3050

Labrador-Horrillo, 2013 [72]

Spain

> 6

Omalizumab

107

133

77.3

2–1042

Maurer, 2013 [73]

Various countries

> 6

Omalizumab or Placebo

322

168 (232)

78

30 (SC)

Rottem 2014 [74]

Israel

> 6

Omalizumab

43

151 (255)

88

Saini, 2015 [35]

Various countries

> 6

Omalizumab or Placebo

318

83

16 (SC)

1–5000

Ensina, 2016 [75]

Brazil

Omalizumab

27

159

0.2–774

Gomez-Vera, 2016 [25]

Mexico

> 6

Omalizumab

26

55.5

31.5–186

Wilches, 2016 [76]

Ecuador

> 6

Omalizumab

26

571

55–2500

Deza 2017 [77]

Spain

> 6

Omalizumab

47

116

42–277

Gericke, 2017 [78]

Germany

> 6

Omalizumab

56

205 (230)

Jorg, 2017 [79]

Switzerland

> 6

Omalizumab or Placebo

30

137 (37.8–311)

AH, SC allowed

Metz, 2017 [80]

Germany

> 6

Omalizumab

20

432 (1031)

3 (AH), 30 (SC)

   

Placebo

10

184 (242)

3 (AH), 30 (SC)

Nettis, 2017 [81]

Italy

> 6

Omalizumab

290

235 (526)

120

73.5

Allowed (AH, SC)

0–5237

Yang, 2017 [82]

Taiwan

> 6

Omalizumab

17

272.6

23.5

8.9–1510

Bulur, 2018 [83]

Turkey

> 6

Omalizumab

132

54.4 (150)

65

62.1

Allowed (AH, SC)

7–978.9

Ertas, 2018 [84]

Turkey

> 6

Omalizumab

96

66.8

20.4–127

Ghazanfar, 2018 [85]

Denmark

> 6

Omalizumab

117

467 (1076)

Allowed (AH)

Hide, 2018 [86]

Japan

> 6

Omalizumab 150 mg

71

335

26.5

30

15–2360

   

Omalizumab 300 mg

73

428

37.1

 

20–4950

   

Placebo

73

414

36.1

 

0–5600

Türk, 2018 [87]

Turkey

> 6

Omalizumab

25

226

56–340

  1. AH antihistamine, SC systemic corticosteroids